Illumina Future Growth

Future criteria checks 4/6

Illumina is forecast to grow earnings and revenue by 69% and 5% per annum respectively. EPS is expected to grow by 73.6% per annum. Return on equity is forecast to be 20.1% in 3 years.

Key information

69.0%

Earnings growth rate

73.6%

EPS growth rate

Life Sciences earnings growth	18.3%
Revenue growth rate	5.0%
Future return on equity	20.1%
Analyst coverage	Good
Last updated	06 Nov 2024

Recent future growth updates

Recent updates

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

May 26

Illumina: Expect A Slow Rebound

May 07

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Apr 26

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Mar 20

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Feb 23

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Jan 26

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Jan 19

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22

The Big Trends: New Frontiers in Healthcare

Jul 13

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14

Earnings and Revenue Growth Forecasts

NasdaqGS:ILMN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4,819	685	1,301	1,463	18
12/31/2025	4,511	524	1,503	1,418	23
12/31/2024	4,318	-873	962	1,011	20
9/29/2024	4,390	-1,585	546	697	N/A
6/30/2024	4,429	-3,044	357	520	N/A
3/31/2024	4,493	-1,290	366	545	N/A
12/31/2023	4,504	-1,161	282	478	N/A
10/1/2023	4,465	-1,124	168	401	N/A
7/2/2023	4,461	-4,186	-224	210	N/A
4/2/2023	4,448	-4,487	-228	230	N/A
1/1/2023	4,584	-4,404	-74	392	N/A
10/2/2022	4,700	-4,153	79	527	N/A
7/3/2022	4,693	-20	53	307	N/A
4/3/2022	4,656	701	208	435	N/A
1/2/2022	4,526	762	337	545	N/A
10/3/2021	4,280	907	469	669	N/A
7/4/2021	3,966	769	898	1,094	N/A
4/4/2021	3,473	630	890	1,081	N/A
1/3/2021	3,239	656	891	1,080	N/A
9/27/2020	3,238	638	933	1,117	N/A
6/28/2020	3,351	693	1,046	1,231	N/A
3/29/2020	3,556	942	941	1,134	N/A
12/29/2019	3,543	1,002	842	1,051	N/A
9/29/2019	3,458	973	691	908	N/A
6/30/2019	3,405	938	701	933	N/A
3/31/2019	3,397	851	823	1,085	N/A
12/30/2018	3,333	826	846	1,142	N/A
9/30/2018	3,243	684	829	1,136	N/A
7/1/2018	3,103	648	N/A	1,079	N/A
4/1/2018	2,936	567	N/A	962	N/A
12/31/2017	2,752	725	N/A	875	N/A
10/1/2017	2,594	775	N/A	843	N/A
7/2/2017	2,487	741	N/A	784	N/A
4/2/2017	2,424	730	N/A	848	N/A
1/1/2017	2,398	454	N/A	779	N/A
10/2/2016	2,371	440	N/A	757	N/A
7/3/2016	2,314	430	N/A	762	N/A
4/3/2016	2,253	415	N/A	692	N/A
1/3/2016	2,220	462	N/A	786	N/A
9/27/2015	2,141	510	N/A	560	N/A
6/28/2015	2,071	486	N/A	524	N/A
3/29/2015	1,979	430	N/A	531	N/A
12/28/2014	1,861	353	N/A	501	N/A
9/28/2014	1,736	281	N/A	488	N/A
6/29/2014	1,612	219	N/A	425	N/A
3/30/2014	1,511	208	N/A	336	N/A
12/29/2013	1,421	125	N/A	386	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ILMN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: ILMN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ILMN is expected to become profitable in the next 3 years.

Revenue vs Market: ILMN's revenue (5% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: ILMN's revenue (5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ILMN's Return on Equity is forecast to be high in 3 years time (20.1%)

Illumina Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Consensus EPS estimates upgraded to US$9.60 loss

Consensus EPS estimates fall from profit to US$1.71 loss

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Recent updates

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina: Q3 Confirms Improving Fundamentals

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina to Preview Newest Innovations in NGS and Multiomic Technologies At the American Society of Human Genetics Annual Meeting

We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Illumina, Inc. Introduces the MiSeq i100 Series

Illumina, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Consensus EPS estimates fall from profit to US$1.71 loss

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Now 24% overvalued

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Now 22% overvalued

Illumina: Expect A Slow Rebound

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Price target decreased by 7.0% to US$224

Second quarter 2023 earnings: EPS misses analyst expectations